|
|
Title: Methods and compositions
for treating gastroparesis
United States Patent: 6,979,562
Issued: December 27, 2005
Inventors: Cheung; Ling Yuk (New
Territories, HK)
Assignee: Ultra Biotech Limited (Douglas,
GB)
Appl. No.: 717132
Filed: November 18, 2003
|
|
|
Outsourcing Guide
|
Abstract
Compositions comprising a plurality of
yeast cells, wherein said plurality of yeast cells are characterized by
their ability to treat gastroparesis in a subject (e.g., stimulating
stomach contraction, reducing abnormal gastric acid and/or pepsin
production), as a result of having been cultured in the presence of an
alternating electric field having a specific frequency and a specific
field strength. Also included are methods of making and using such
compositions.
DETAILED DESCRIPTION
OF THE INVENTION
This invention is based on the discovery
that certain yeast strains can be activated by electromagnetic fields ("EMF")
having specific frequencies and field strengths to become highly efficient
in producing substances that increase the bioelectrical activities of the
stomach, reduce abnormal gastric acid secretion and/or abnormal pepsin
production in a subject. Compositions containing these activated yeast
cells are therefore useful in the treatment of gastroparesis. Yeast
compositions containing activated yeast cells can be used as medication or
dietary supplements.
Since the activated yeast cells contained in the yeast compositions have
been cultured to endure acidic conditions (pH 2.5-4.2), these cells can
survive the gastric environment and pass on to the intestines. Once in the
intestines, the yeast cells are ruptured by various digestive enzymes, and
the anti-gastroparesis substances are released and readily absorbed.
I. Yeast Strains Useful in the Invention
The types of yeasts useful in this invention include, but are not limited
to, yeasts of the genera Saccharomyces, Schizosaccharomyces, and
Rhodotorula.
Exemplary species within the above-listed genera include, but are not
limited to, those illustrated in Table 1. Yeast strains useful for this
invention can be obtained from laboratory cultures, or from publically
accessible culture depositories, such as CGMCC and the American Type
Culture Collection, 10801 University Boulevard, Manassas, Va. 20110-2209.
Non-limiting examples of useful strains (with accession numbers of CGMCC)
are Saccharomyces cerevisiae Hansen AS2.559 Saccharomyces
sp. AS2.311, Schizosaccharomyces pombe Lindner AS2.994,
Saccharomyces sake Yabe ACCC2045, Saccharomyces uvarum Beijer
IFFI1044, Saccharomyces rouxii Boutroux AS2.180, Saccharomyces
cerevisiae Hansen Var. ellipsoideus AS2.612, Saccharomyces
carlsbergensis Hansen AS2.377, Rhodotorula rubar (Demme)
Lodder AS2.282 and Saccharomyces cerevisiae Hansen AS2.69.
Other useful yeast strains are illustrated in Table 1.
Although it is preferred, the preparation of the yeast compositions of
this invention is not limited to starting with a pure strain of yeast. A
yeast composition of the invention may be produced by culturing a mixture
of yeast cells of different species or strains. The ability of any
activated species or strain of yeasts to treat gastroparesis can be
readily tested by methods known in the art. See, for instance, Examples 1
and 2.
| TABLE 1 |
| |
| Exemplary Yeast Strains |
| |
| Saccharomyces cerevisiae
Hansen |
| ACCC2034 |
ACCC2035 |
ACCC2036 |
ACCC2037 |
ACCC2038 |
| ACCC2039 |
ACCC2040 |
ACCC2041 |
ACCC2042 |
AS2.1 |
| AS2.4 |
AS2.11 |
AS2.14 |
AS2.16 |
AS2.56 |
| AS2.69 |
AS2.70 |
AS2.93 |
AS2.98 |
AS2.101 |
| AS2.109 |
AS2.110 |
AS2.112 |
AS2.139 |
AS2.173 |
| AS2.174 |
AS2.182 |
AS2.196 |
AS2.242 |
AS2.336 |
| AS2.346 |
AS2.369 |
AS2.374 |
AS2.375 |
AS2.379 |
| AS2.380 |
AS2.382 |
AS2.390 |
AS2.393 |
AS2.395 |
| AS2.396 |
AS2.397 |
AS2.398 |
AS2.399 |
AS2.400 |
| AS2.406 |
AS2.408 |
AS2.409 |
AS2.413 |
AS2.414 |
| AS2.415 |
AS2.416 |
AS2.422 |
AS2.423 |
AS2.430 |
| AS2.431 |
AS2.432 |
AS2.451 |
AS2.452 |
AS2.453 |
| AS2.458 |
AS2.460 |
AS2.463 |
AS2.467 |
AS2.486 |
| AS2.501 |
AS2.502 |
AS2.503 |
AS2.504 |
AS2.516 |
| AS2.535 |
AS2.536 |
AS2.558 |
AS2.560 |
AS2.561 |
| AS2.562 |
AS2.576 |
AS2.593 |
AS2.594 |
AS2.614 |
| AS2.620 |
AS2.628 |
AS2.631 |
AS2.666 |
AS2.982 |
| AS2.1190 |
AS2.1364 |
AS2.1396 |
IFFI1001 |
IFFI1002 |
| IFFI1005 |
IFFI1006 |
IFFI1008 |
IFFI1009 |
IFFI1010 |
| IFFI1012 |
IFFI1021 |
IFFI1027 |
IFFI1037 |
IFFI1042 |
| IFFI1043 |
IFFI1045 |
IFFI1048 |
IFFI1049 |
IFFI1050 |
| IFFI1052 |
IFFI1059 |
IFFI1060 |
IFFI1062 |
IFFI1063 |
| IFFI1202 |
IFFI1203 |
IFFI1206 |
IFFI1209 |
IFFI1210 |
| IFFI1211 |
IFFI1212 |
IFFI1213 |
IFFI1214 |
IFFI1215 |
| IFFI1220 |
IFFI1221 |
IFFI1224 |
IFFI1247 |
IFFI1248 |
| IFFI1251 |
IFFI1270 |
IFFI1277 |
IFFI1287 |
IFFI1289 |
| IFFI1290 |
IFFI1291 |
IFFI1292 |
IFFI1293 |
IFFI1297 |
| IFFI1300 |
IFFI1301 |
IFFI1302 |
IFFI1307 |
IFFI1308 |
| IFFI1309 |
IFFI1310 |
IFFI1311 |
IFFI1331 |
IFFI1335 |
| IFFI1336 |
IFFI1337 |
IFFI1338 |
IFFI1339 |
IFFI1340 |
| IFFI1345 |
IFFI1348 |
IFFI1396 |
IFFI1397 |
IFFI1399 |
| IFFI1411 |
IFFI1413 |
IFFI1441 |
IFFI1443 |
| Saccharomyces cerevisiae
Hansen Var. ellipsoideus (Hansen) Dekker |
| ACCC2043 |
AS2.2 |
AS2.3 |
AS2.8 |
AS2.53 |
| AS2.163 |
AS2.168 |
AS2.483 |
AS2.541 |
AS2.559 |
| AS2.606 |
AS2.607 |
AS2.611 |
AS2.612 |
| Saccharomyces chevalieri
Guilliermond |
| Saccharomyces delbrueckii |
| Saccharomyces delbrueckii
Lindner ver. mongolicus |
| (Saito) Lodder et van Rij |
| Saccharomyces exiguous
Hansen |
| Saccharomyces fermentati
(Saito) Lodder et van Rij |
| Saccharomyces logos
van laer et Denamur ex Jorgensen |
| Saccharomyces mellis
(Fabian et Quinet) Lodder et kreger van
Rij |
| Saccharomyces mellis
Microellipsoides Osterwalder |
| Saccharomyces oviformis
Osteralder |
| Saccharomyces rosei
(Guilliermond) Lodder et Kreger van Rij |
| Saccharomyces rouxii
Boutroux |
| AS2.178 |
AS2.180 |
AS2.370 |
AS2.371 |
| Candida lambica
(Lindner et Genoud) van. Uden et Buckley |
| Candida krusei
(Castellani) Berkhout |
| Candida lipolytica
(Harrison) Diddens et Lodder |
| AS2.1207 |
AS2.1216 |
AS2.1220 |
AS2.1379 |
AS2.1398 |
| Candida parapsilosis
(Ashford) Langeron et Talice Var. |
| intermedia Van Rij et Verona |
| Candida parapsilosis
(Ashford) Langeron et Talice |
| Candida pulcherrima
(Lindner) Windisch |
| Candida rugousa
(Anderson) Diddens et Lodder |
| AS2.511 |
AS2.1367 |
AS2.1369 |
AS2.1372 |
AS2.1373 |
| AS2.1377 |
AS2.1378 |
AS2.1384 |
| Candida tropicalis
(Castellani) Berkhout |
| ACCC2004 |
ACCC2005 |
ACCC2006 |
AS2.164 |
AS2.402 |
| AS2.564 |
AS2.565 |
AS2.567 |
AS2.568 |
AS2.617 |
| AS2.637 |
AS2.1387 |
AS2.1397 |
| Candida utilis
Henneberg Lodder et Kreger Van Rij |
| Crebrothecium ashbyii
(Guillermond) |
| Routein (Eremothecium ashbyii
Guilliermond) |
| ACCC2016 |
AS2.361 |
AS2.498 |
AS2.616 |
AS2.1035 |
| AS2.1062 |
AS2.1080 |
AS2.1132 |
AS2.1175 |
AS2.1183 |
| Hansenula anomala
(Hansen)H et P sydow |
| ACCC2018 |
AS2.294 |
AS2.295 |
AS2.296 |
AS2.297 |
| AS2.298 |
AS2.299 |
AS2.300 |
AS2.302 |
AS2.338 |
| AS2.339 |
AS2.340 |
AS2.341 |
AS2.470 |
AS2.592 |
| AS2.641 |
AS2.642 |
AS2.782 |
AS2.635 |
AS2.794 |
| Hansenula arabitolgens
Fang |
| Hansenula jadinii
(A. et R Sartory Weill et Meyer) Wickerham |
| Hansenula saturnus
(Klocker) H et P sydow |
| Hansenula schneggii
(Weber) Dekker |
| Hansenula subpelliculosa
Bedford |
| AS2.740 |
AS2.760 |
AS2.761 |
AS2.770 |
AS2.783 |
| AS2.790 |
AS2.798 |
AS2.866 |
| Kloeckera apiculata
(Reess emend. Klocker) Janke |
| ACCC2022 |
ACCC2023 |
AS2.197 |
AS2.496 |
AS2.714 |
| ACCC2021 |
AS2.711 |
| Lipomycess starkeyi
Lodder et van Rij |
| Pichia farinosa
(Lindner) Hansen |
| ACCC2025 |
ACCC2026 |
AS2.86 |
AS2.87 |
AS2.705 |
| AS2.803 |
| Pichia membranaefaciens
Hansen |
| ACCC2027 |
AS2.89 |
AS2.661 |
AS2.1039 |
| Rhodosporidium toruloides
Banno |
| Rhodotorula glutinis
(Fresenius) Harrison |
| AS2.2029 |
AS2.280 |
ACCC2030 |
AS2.102 |
AS2.107 |
| AS2.278 |
AS2.499 |
AS2.694 |
AS2.703 |
AS2.704 |
| AS2.1146 |
| Rhodotorula minuta
(Saito) Harrison |
| Rhodotorula rubar
(Demme) Lodder |
| AS2.21 |
AS2.22 |
AS2.103 |
AS2.105 |
AS2.108 |
| AS2.140 |
AS2.166 |
AS2.167 |
AS2.272 |
AS2.279 |
| AS2.282 |
ACCC2031 |
| Rhodotorula aurantiaca
(Saito) Lodder |
| AS2.102 |
AS2.107 |
AS2.278 |
AS2.499 |
AS2.694 |
| AS2.703 |
AS2.1146 |
| Saccharomyces
carlsbergensis Hansen |
| AS2.113 |
ACCC2032 |
ACCC2033 |
AS2.312 |
AS2.116 |
| AS2.118 |
AS2.121 |
AS2.132 |
AS2.162 |
AS2.189 |
| AS2.200 |
AS2.216 |
AS2.265 |
AS2.377 |
AS2.417 |
| AS2.420 |
AS2.440 |
AS2.441 |
AS2.443 |
AS2.444 |
| AS2.459 |
AS2.595 |
AS2.605 |
AS2.638 |
AS2.742 |
| AS2.745 |
AS2.748 |
AS2.1042 |
| Saccharomyces uvarum
Beijer |
| IFFI1023 |
IFFI1032 |
IFFI1036 |
IFFI1044 |
IFFI1072 |
| IFFI1205 |
IFFI1207 |
| Saccharomyces willianus
Saccardo |
| AS2.5 |
AS2.7 |
AS2.119 |
AS2.152 |
AS2.293 |
| AS2.381 |
AS2.392 |
AS2.434 |
AS2.614 |
AS2.1189 |
| Saccharomycodes ludwigii
Hansen |
| Saccharomycodes sinenses
Yue |
| Schizosaccharomyces
octosporus Beijerinck |
| Schizosaccharomyces pombe
Lindner |
| ACCC2047 |
ACCC2048 |
AS2.214 |
AS2.248 |
AS2.249 |
| AS2.255 |
AS2.257 |
AS2.259 |
AS2.260 |
AS2.274 |
| AS2.994 |
AS2.1043 |
AS2.1149 |
AS2.1178 |
IFFI1056 |
| Sporobolomyces roseus
Kluyver et van Niel |
| ACCC2049 |
ACCC2050 |
AS2.19 |
AS2.962 |
AS2.1036 |
| ACCC2051 |
AS2.261 |
AS2.262 |
| Torulopsis candida
(Saito) Lodder |
| Torulopsis famta
(Harrison) Lodder et van Rij |
| Torulopsis globosa
(Olson et Hammer) Lodder et van Rij |
| Torulopsis inconspicua
Lodder et Kreger van Rij |
| Trichosporon behrendii
Lodder et Kreger van Rij |
| Trichosporon capitatum
Diddens et Lodder |
| Trichosporon cutaneum
(de Beurm et al.) Ota |
| ACCC2057 |
AS2.25 |
AS2.570 |
AS2.571 |
AS2.1374 |
| Wickerhamia fluorescens
(Soneda) Soneda |
II. Application of Electromagnetic Fields
An electromagnetic field useful in this invention can be generated and
applied by various means well known in the art. For instance, the EMF can
be generated by applying an alternating electric field or an oscillating
magnetic field.
Alternating electric fields can be applied to cell cultures through
electrodes in direct contact with the culture medium, or through
electromagnetic induction. See, e.g., FIG. 1 (see Original Patent).
Relatively high electric fields in the medium can be generated using a
method in which the electrodes are in contact with the medium. Care must
be taken to prevent electrolysis at the electrodes from introducing
undesired ions into the culture and to prevent contact resistance,
bubbles, or other features of electrolysis from dropping the field level
below that intended. Electrodes should be matched to their environment,
for example, using Ag—AgCl electrodes in solutions rich in chloride ions,
and run at as low a voltage as possible. For general review, see Goodman
et al., Effects of EMF on Molecules and Cells, International Review
of Cytology, A Survey of Cell Biology, Vol. 158, Academic Press, 1995.
The EMFs useful in this invention can also be generated by applying an
oscillating magnetic field. An oscillating magnetic field can be generated
by oscillating electric currents going through Helmholtz coils. Such a
magnetic field in turn induces an electric field.
The frequencies of EMFs useful in this invention range from about 9500 to
13500 MHz (e.g., 9500-10500, 11700-12700 and 12200-13200 MHz). Exemplary
frequencies are 10012, 10038, 12177, 12712 and 12733 MHz. The field
strength of the electric field useful in this invention ranges from about
200-450 mV/cm (e.g., 235-255, 240-260, 250-270, 255-275, 265-285, 275-295,
280-300, 290-310, 290-320, 330-350 and 360-380 mV/cm). Exemplary field
strengths are 253, 255, 260, 277, 279, 280, 290, 293, 294, 314, 343 and
364 mV/cm.
When a series of EMFs are applied to a yeast culture, the yeast culture
can remain in the same container while the same set of EMF generator and
emitters is used to change the frequency and/or field strength. The EMFs
in the series can each have a different frequency or a different field
strength; or a different frequency and a different field strength. Such
frequencies and field strengths are preferably within the above-described
ranges. Although any practical number of EMFs can be used in a series, it
may be preferred that the yeast culture be exposed to a total of, for
example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or more EMFs in a series.
In one embodiment, the yeast culture is exposed to a series of EMFs,
wherein the frequency of the electric field is alternated in the range of
9500-10500, 11700-12700 and 12200-13200 MHz.
Although the yeast cells can be activated after even a few hours of
culturing in the presence of an EMF, it may be preferred that the
activated yeast cells be allowed to multiply and grow in the presence of
the EMF(s) for a total of 10-50 hours.
FIG. 1 illustrates an exemplary apparatus for generating alternating
electric fields. An electric field of a desired frequency and intensity is
generated by an AC source (3) capable of generating an alternating
electric field, preferably in a sinusoidal wave form, in the frequency
range of 10 to 20,000 MHz. Signal generators capable of generating signals
with a narrower frequency range can also be used. If desirable, a signal
amplifier can also be used to increase the output. The activation
container (2) can be made from non-conductive material, e.g.,
plastics, glass or ceramic. The wire connecting the activation container (2)
and the signal generator (3) is preferably a high frequency coaxial
cable with a transmission frequency of at least 30 GHz.
The alternating electric field can be applied to the culture by a variety
of means, including placing the yeast culture (1) in close
proximity to the signal emitters such as a metal wire or tube capable of
transmitting EMFs. The metal wire or tube can be made of red copper, and
be placed inside the container (2), reaching as deep as 3-30 cm.
For example, if the fluid in the container (2) has a depth of 15-20
cm, 20-30 cm, 30-50 cm, 50-70 cm, 70-100 cm, 100-150 cm or 150-200 cm, the
metal wire can be 3-5 cm, 5-7 cm, 7-10 cm, 10-15 cm, 15-20 cm, 20-30 cm
and 25-30 cm from the bottom of the container (2), respectively.
The number of electrode wires used depends on the volume of the culture as
well as the diameter of the wires. The number of metal wires/tubes used
can be from 1 to 10 (e.g., 2 to 3). It is recommended, though not
mandated, that for a culture having a volume up to 10 L, metal wires/tubes
having a diameter of 0.5 to 2.0 mm be used. For a culture having a volume
between 10 L and 100 L, metal wires/tubes having a diameter of 3.0 to 5.0
mm can be used. For a culture having a volume in the range of 100-1000 L,
metal wires/tubes having a diameter of 6.0 to 15.0 mm can be used. For a
culture having a volume greater than 1000 L, metal wires/tubes having a
diameter of 20.0 to 25.0 mm can be used.
In one embodiment, the electric field is applied by electrodes submerged
in the culture (1). In this embodiment, one of the electrodes can
be a metal plate placed on the bottom of the container (2), and the
other electrode can comprise a plurality of electrode wires evenly
distributed in the culture (1) so as to achieve even distribution
of the electric field energy. The number of electrode wires used depends
on the volume of the culture as well as the diameter of the wires.
III. Culture Media
Culture media useful in this invention contain sources of nutrients
assimilable by yeast cells. Complex carbon-containing substances in a
suitable form, such as carbohydrates (e.g., sucrose, glucose, fructose,
dextrose, maltose, xylose, cellulose, starches, etc.) and coal, can be the
carbon sources for yeast cells. The exact quantity of the carbon sources
utilized in the medium can be adjusted in accordance with the other
ingredients of the medium. In general, the amount of carbohydrates varies
between about 0.1% and 10% by weight of the medium and preferably between
about 0.1% and 5% (e.g., about 2%). These carbon sources can be used
individually or in combination. Amino acid-containing substances in
suitable form (e.g., beef extract and peptone) can also be added
individually or in combination. In general, the amount of amino acid
containing substances varies between about 0.1% and 0.5% by weight of the
medium and preferably between about 0.1% and 0.3% (e.g., about 0.25%).
Among the inorganic salts which can be added to the culture medium are the
customary salts capable of yielding sodium, potassium, calcium, phosphate,
sulfate, carbonate, and like ions. Non-limiting examples of nutrient
inorganic salts are (NH4)2HPO4, KH2PO4,
K2HPO4, CaCO3, MgSO4, NaCl,
and CaSO4.
IV. Electromagnetic Activation of Yeast Cells
To activate or enhance the ability of yeast cells to produce substances
beneficial for the treatment of gastroparesis (e.g., stimulating stomach
contraction), these cells can be activated by being cultured in an
appropriate medium under sterile conditions at 20° C.-38° C., preferably
at 28-32° C. (e.g., 30° C.) for a sufficient amount of time, e.g., 10-50
hours, in an alternating electric field or a series of alternating
electric fields as described above.
An exemplary culture medium is made by mixing 1000 ml of distilled water
with 18 g of mannitol, 20 μg of vitamin B12, 40 μg of vitamin B6,
10 μg of vitamin D, 35 ml of fetal bovine serum, 0.20 g of KH2PO4,
0.25 g of MgSO4.7H2O, 0.3 g of NaCl, 0.2 g of CaSO4.2H2O,
4.0 g of CaCO3.5H2O, and 2.5 g of peptone.
An exemplary set-up of the culturing process is depicted in FIG. 1.
Untreated yeast cells are added to a culture medium at 1×108
cells per 1000 ml of the culture medium. The yeast cells may be
Saccharomyces cerevisiae Hansen AS2.559, or may be selected from any
of the strains listed in Table 1. An exemplary activation process of the
yeast cells involves the following sequence: the yeast cells are grown in
the culture medium for 23-43 hours (e.g., 28 hours) at 28-32° C. and then
exposed to (1) an alternating electric field having a frequency of 10012
MHz and a field strength in the range of 240-260 mV/cm (e.g., 255 mV/cm)
for 7-17 hours (e.g., 12 hours); (2) then to an alternating electric field
having a frequency of 10038 MHz and a field strength in the range of
235-255 mV/cm (e.g., 253 mV/cm) for 31-41 hours (e.g., 36 hours); (3) then
to an alternating electric field having a frequency of 12177 MHz and a
field strength in the range of 265-285 mV/cm (e.g., 277 mV/cm) for 36-46
hours (e.g., 41 hours); (4) then to an alternating electric field having a
frequency of 12712 MHz and a field strength in the range of 290-310 mV/cm
(e.g., 294 mV/cm) for 20-30 hours (e.g., 25 hours); and (5) finally to an
alternating electric field having a frequency of 12733 MHz and a field
strength in the range of 255-275 mV/cm (e.g., 260 mV/cm) for 10-20 hours
(e.g., 15 hours). The activated yeast cells are then recovered from the
culture medium by various methods known in the art, dried (e.g., by
lyophilization) and stored at about 4° C. in powder form. The resultant
yeast powder preferably contains no less than 1010 cells/g
activated yeast.
Subsequently, the activated yeast cells can be evaluated for their ability
to treat gastroparesis using standard methods known in the art, such as
those described in Section VII.
V. Acclimatization of Yeast Cells to the Gastric Environment
Because the activated yeast cells of this invention must pass through the
stomach before reaching the small intestine, where the effective
components are released from these yeast cells, it is preferred that these
yeasts be cultured under acidic conditions so as to acclimatize the cells
to the gastric juice. This acclimatization process results in better
viability of the yeast cells in the acidic gastric environment.
To achieve this, the yeast powder containing activated yeast cells can be
mixed with a highly acidic acclimatizing culture medium at 10 g
(containing more than 1010 activated cells per gram) per 1000
ml. The yeast mixture can then be cultured first in the presence of an
alternating electric field having a frequency of 12712 MHz and a field
strength in the range of 290-320 mV/cm (e.g., 314 mV/cm) at about 28 to
32° C. for 36-42 hours (e.g., 38 hours). The resultant yeast cells can
then be further incubated in the presence of an alternating electric field
having a frequency of 12733 MHz and a field strength in the range of
275-295 mV/cm (e.g., 290 mV/cm) at about 28 to 32° C. for 16-28 hours
(e.g., 20 hours). The resulting acclimatized yeast cells are then
recovered from the culture medium by various methods known in the art and
are dried and stored either in powder form (≧1010 cells/g) at
room temperature or in vacuum at 0-4° C.
An exemplary acclimatizing culture medium is made by mixing 700 ml fresh
pig gastric juice and 300 ml wild Chinese hawthorn extract. The pH of
acclimatizing culture medium is adjusted to 2.5 with 0.1 M hydrochloric
acid (HCl) and 0.2 M potassium hydrogen phthalate (C6H4(COOK)COOH).
The fresh pig gastric juice is prepared as follows. At about 4 months of
age, newborn Holland white pigs are sacrificed, and the entire contents of
their stomachs are retrieved and mixed with 2000 ml of water under sterile
conditions. The mixture is then allowed to stand for 6 hours at 4° C.
under sterile conditions to precipitate food debris. The supernatant is
collected for use in the acclimatizing culture medium. To prepare the wild
Chinese hawthorn extract, 500 g of fresh wild Chinese hawthorn is dried
under sterile conditions to reduce water content (≦8%). The dried fruit is
then ground (≧20 mesh) and added to 1500 ml of sterile water. The hawthorn
slurry is allowed to stand for 6 hours at 4° C. under sterile conditions.
The hawthorn supernatant is collected to be used in the acclimatizing
culture medium.
VI. Manufacture of Yeast Compositions
To prepare the yeast compositions of the invention, an apparatus depicted
in FIG. 2 or an equivalent thereof can be used. This apparatus includes
three containers, a first container (A), a second container (B), and a
third container (C), each equipped with a pair of electrodes (4).
One of the electrodes is a metal plate placed on the bottom of the
containers, and the other electrode comprises a plurality of electrode
wires evenly distributed in the space within the container to achieve even
distribution of the electric field energy. All three pairs of electrodes
are connected to a common signal generator.
The culture medium used for this purpose is a mixed fruit extract solution
containing the following ingredients per 1000 L: 300 L of wild Chinese
hawthorn extract, 300 L of jujube extract, 300 L of Schisandra
chinensis (Turez) Baill seeds extract, and 100 L of soy
bean extract. To prepare hawthorn, jujube and Schisandra chinensis
(Turez) Baill seeds extracts, the fresh fruits are washed
and dried under sterile conditions to reduce the water content to no
higher than 8%. One hundred kilograms of the dried fruits are then ground
(≧20 mesh) and added to 400 L of sterilized water. The mixtures are
stirred under sterile conditions at room temperature for twelve hours, and
then centrifuged at 1000 rpm to remove insoluble residues. To make the soy
bean extract, fresh soy beans are washed and dried under sterile
conditions to reduce the water content to no higher than 8%. Thirty
kilograms of dried soy beans are then ground into particles of no smaller
than 20 mesh, and added to 130 L of sterilized water. The mixture is
stirred under sterile conditions at room temperature for twelve hours and
centrifuged at 1000 rpm to remove insoluble residues. Once the mixed fruit
extract solution is prepared, it is autoclaved at 121° C. for 30 minutes
and cooled to below 40° C. before use.
One thousand grams of the activated yeast powder prepared as described
above (Section V, supra) is added to 1000 L of the mixed fruit extract
solution, and the yeast solution is transferred to the first container (A)
shown in FIG. 2. The yeast cells are then cultured in the presence
of an alternating electric field having a frequency of 12712 MHz and a
field strength of about 360-380 mV/cm (e.g., 364 mV/cm) at 28-32° C. under
sterile conditions for 19-29 hours (e.g., 24 hours). The yeast cells are
further incubated in an alternating electric field having a frequency of
12733 MHz and a field strength of 280-300 mV/cm (e.g., 293 mV/cm). The
culturing continues for 7-17 hours (e.g., 12 hours).
The yeast culture is then transferred from the first container (A) to the
second container (B) (if need be, a new batch of yeast culture can be
started in the now available the first container (A)), and subjected to an
alternating electric field having a frequency of 12712 MHz and a field
strength of 265-285 mV/cm (e.g., 279 mV/cm) for 19-29 hours (e.g., 24
hours). Subsequently the frequency and field strength of the electric
field are changed to 12733 MHz and 250-270 mV/cm (e.g., 260 mV/cm),
respectively. The culturing process continues for 7-17 hours (e.g., 12
hours).
The yeast culture is then transferred from the second container (B) to the
third container (C), and subjected to an alternating electric field having
a frequency of 12712 MHz and a field strength of 265-285 mV/cm (e.g., 279
mV/cm) for 19-29 hours (e.g., 24 hours). Subsequently the frequency and
field strength of the electric field are changed to 12733 MHz and 250-270
mV/cm (e.g., 260 mV/cm), respectively. The culturing continues for 7-17
hours (e.g., 12 hours).
The yeast culture from the third container (C) can then be packaged into
vacuum sealed bottles for use as dietary supplement or medication. The
compositions may be conveniently formulated as health drinks. If desired,
the final yeast culture can also be dried within 24 hours and stored in
powder form. The dietary supplement or medication can be taken three to
four times daily at 30˜50 ml or 100 ml per bottle for a three-month period
(preferably a six-month period), preferably 10-30 minutes before meals and
at bedtime.
In some embodiments, the compositions of the invention can also be
administered intravenously or peritoneally in the form of a sterile
injectable preparation. Such a sterile preparation can be prepared as
follows. A sterilized health drink composition is first treated under
ultrasound (≧18000 Hz) for 10 minutes and then centrifuged at 4355 rpm for
another 10 minutes. The resulting supernatant is adjusted to pH 7.2-7.4
using 1 M NaOH and subsequently filtered through a membrane (0.22 μm for
intravenous injection and 0.45 μm for peritoneal injection) under sterile
conditions. The resulting sterile preparation is submerged in a 35-38° C.
water bath for 30 minutes before use. In other embodiments, the
compositions of the invention may also be formulated with pharmaceutically
acceptable carriers to be orally administered in any orally acceptable
dosage form including, but not limited to, capsules, tablets, suspensions
or solutions.
The yeast compositions of the present invention are derived from yeasts
used in food and pharmaceutical industries. The yeast compositions are
thus devoid of side effects associated with many pharmaceutical compounds.
Claim 1 of 12 Claims
1. A composition comprising a
plurality of yeast cells, wherein said plurality of yeast cells are
characterized by their ability to treat gastroparesis in a subject, as a
result of having been cultured in the presence of an alternating electric
field having a frequency in the range of 9500 to 13500 MHz and a field
strength in the range of 200 to 450 mV/cm, as compared to yeast cells not
having been so cultured.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|